127 related articles for article (PubMed ID: 17996426)
1. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
Thomson KS; Black J; Moland ES; Reuben J; Wiles T; Brasso W
Int J Antimicrob Agents; 2008 Jan; 31(1):83-5. PubMed ID: 17996426
[No Abstract] [Full Text] [Related]
2. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
3. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
4. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
[TBL] [Abstract][Full Text] [Related]
5. Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.
Shubert C; Slaughter J; Creely D; van Belkum A; Gayral JP; Dunne WM; Zambardi G; Shortridge D
Antimicrob Agents Chemother; 2014; 58(3):1779-81. PubMed ID: 24342642
[TBL] [Abstract][Full Text] [Related]
6. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
[No Abstract] [Full Text] [Related]
7. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
[TBL] [Abstract][Full Text] [Related]
8. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
[No Abstract] [Full Text] [Related]
9. Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam.
dos Santos KV; Diniz CG; Veloso Lde C; de Andrade HM; Giusta Mda S; Pires Sda F; Santos AV; Apolônio AC; de Carvalho MA; Farias Lde M
Res Microbiol; 2010 May; 161(4):268-75. PubMed ID: 20381611
[TBL] [Abstract][Full Text] [Related]
10. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
Marchaim D; Sunkara B; Lephart PR; Gudur UM; Bhargava A; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Chopra T; Dhar S; Kaye KS
Infect Control Hosp Epidemiol; 2012 Aug; 33(8):853-5. PubMed ID: 22759556
[No Abstract] [Full Text] [Related]
11. In-vitro evaluation of "piperacillin and tazobactum" combination in a tertiary-care hospital--a preliminary study.
Kumari N; Mohapatra TM; Rai A; Bhattacharya SK
Indian J Pathol Microbiol; 2006 Jan; 49(1):57-8. PubMed ID: 16625981
[No Abstract] [Full Text] [Related]
12. Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.
Tschudin-Sutter S; Frei R; Widmer AF
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):286-7. PubMed ID: 21353954
[No Abstract] [Full Text] [Related]
13. Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.
Monogue ML; Tanner LK; Brecher SM; Aslanzadeh J; Nicolau DP
Infect Control Hosp Epidemiol; 2017 Mar; 38(3):379-380. PubMed ID: 28069100
[No Abstract] [Full Text] [Related]
14. Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study.
Mohammedi I; Ploin D; Duperret S; Chapuis F; Petit P
Intensive Care Med; 2003 Jul; 29(7):1164-8. PubMed ID: 12774156
[TBL] [Abstract][Full Text] [Related]
15. High rates of resistance to piperacillin/tazobactam among Escherichia coli and Klebsiella pneumoniae strains isolated in a Greek hospital.
Tsakris A; Douboyas J; Tzouvelekis LS
Diagn Microbiol Infect Dis; 1997 Sep; 29(1):39-41. PubMed ID: 9350414
[TBL] [Abstract][Full Text] [Related]
16. International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.
Creely D; Zambardi G; van Belkum A; Dunne WM; Peyret M; Gayral JP; Shortridge D; Shubert C
Eur J Clin Microbiol Infect Dis; 2013 Aug; 32(8):997-1002. PubMed ID: 23397255
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo.
Kuck NA; Petersen PJ; Weiss WJ; Jacobus NV; Testa RT; Tally FP
J Chemother; 1989 Jul; 1(4 Suppl):105-6. PubMed ID: 16312325
[No Abstract] [Full Text] [Related]
18. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.
Stiefel U; Harmoinen J; Koski P; Kääriäinen S; Wickstrand N; Lindevall K; Pultz NJ; Bonomo RA; Helfand MS; Donskey CJ
Antimicrob Agents Chemother; 2005 Dec; 49(12):5190-1. PubMed ID: 16304203
[No Abstract] [Full Text] [Related]
19. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
Jones RN; Fritsche TR; Moet GJ
Diagn Microbiol Infect Dis; 2008 May; 61(1):76-9. PubMed ID: 18221852
[TBL] [Abstract][Full Text] [Related]
20. In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
Monogue ML; Nicolau DP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7527-7529. PubMed ID: 27799205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
